Tarsus (NASDAQ: TARS) ex-officer plans sale of 53K shares
Rhea-AI Filing Summary
Tarsus Pharmaceuticals, Inc. (TARS) received a notice of proposed sale of common stock under Rule 144. Former officer Aziz A. Mottiwala, through Fidelity Brokerage Services LLC, plans to sell 53,043 shares of common stock, expected to be issued from a stock option exercise on 08/19/2026. The filing lists an aggregate market value of $3,819,096.00 for the shares to be sold and 43,882,996 shares of Tarsus common stock outstanding on the NASDAQ.
Positive
- None.
Negative
- None.
Key Figures
Shares to be sold: 53,043 shares
Aggregate market value: $3,819,096.00
Shares outstanding: 43,882,996 shares
+1 more
4 metrics
Shares to be sold
53,043 shares
Common stock proposed to be sold under Rule 144
Aggregate market value
$3,819,096.00
Aggregate market value of 53,043 shares to be sold
Shares outstanding
43,882,996 shares
Tarsus common stock outstanding as listed in the notice
Planned option exercise date
08/19/2026
Date tied to stock option exercise and proposed sale
Key Terms
Rule 144, stock option exercise, aggregate market value, attorney-in-fact
4 terms
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
stock option exercise financial
"Common | 08/19/2026 | Stock Option Exercise | Issuer"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
aggregate market value financial
"Common | Fidelity Brokerage Services LLC ... | 53043 | 3819096.00 |"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
attorney-in-fact regulatory
"as attorney-in-fact for Aziz A. Mottiwala"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.
FAQ
What insider sale is disclosed for Tarsus Pharmaceuticals (TARS) in this Form 144?
The notice reports a proposed sale of 53,043 Tarsus (TARS) common shares by former officer Aziz A. Mottiwala. The shares are tied to a stock option exercise on 08/19/2026, with Fidelity Brokerage Services LLC acting as broker.
Who is the selling security holder in the Tarsus (TARS) Form 144 filing?
The selling security holder is Aziz A. Mottiwala, identified as a former officer of Tarsus Pharmaceuticals (TARS). Fidelity Brokerage Services LLC is named as the broker handling the proposed sale of the shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.